HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System
HeartBeam secures an expedited FDA designation for its 3D ECG at-home heart attack assessment tool, paving the way for rapid clinical trials.
Stocks · News reference
HeartBeam shares are trading higher after the company announced it received the FDA Breakthrough Device Designation for the HeartBeam System as a tool for assessing potential heart attacks at home.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dow Gains 100 Points; ISM Services PMI Falls In September
U.S. stocks rose Monday: Dow +0.2%, S&P 500 +0.62%, Nasdaq +0.84%. Materials led; ISM services PMI slipped to 54.9. Oil fell 1%.
US Stocks Mixed; Nasdaq Gains Over 50 Points
U.S. stocks mixed: Nasdaq and S&P 500 rose while Dow dipped. Weak jobs data pressured outlook; oil fell, while gold, silver and copper gained.